• Slider_A

    I am unique so is my cancer.

    Read More
  • Slider_B

    Personalized insights For more effective treatment.

    Read More
  • Slider_C

    Non-invasive simple starter kit.

    Order Now
  • Slider_D

    Individualized therapy Designed to treat each patient.

    Read More
  • Slider_E

    Available NowPlasmaSelect 64 Specimen Collection Kit

    Order Now
logo top
Scroll Down & Explore

What is MYPG?

fbox-bulb

Knowledge is Power

With MYPG, you can obtain the unique genetic information about your cancer in order to make informed decisions. These results enable your healthcare team to create a personalized treatment plan based on the most up to date therapies and clinical trials.

Cancer is a genetic disease driven by mutations in genes that convert normal cells into cancer cells. Normally, the genes within a cell serve as the instruction manual for how the cell behaves and performs. In cancer, mutations within key genes cause uncontrollable growth and invasion. MYPG sequences the most important cancer genes for mutations that may provide the insight needed to best manage your cancer.

Cancer-Specific Differences

knowledge-is-power-graphic-f1-s1 knowledge-is-power-graphic-f1-s2 knowledge-is-power-graphic-f1-s3
Changes in the genome sequence
knowledge-is-power-graphic-f2-s1 knowledge-is-power-graphic-f2-s2 knowledge-is-power-graphic-f2-s3
Changes in the copy number of specific genes
knowledge-is-power-graphic-f3-s1 knowledge-is-power-graphic-f3-s2 knowledge-is-power-graphic-f3-s3
Rearrangements or joining together of sequences in the genome.
fbox-eyedropper

Our Tests

Information about particular genes in your tumor cells and how they are different from normal cells can help physicians create a more personalized treatment plan for you.

The results from the test may provide more insight into cancer therapy, disease classification, or prognosis. Ongoing clinical trials that target your cancer may be identified.

Personal Genome Diagnostics offers tests to identify specific information about your tumor and its genetic makeup.

our-tests-circle-1-fallback
our-tests-circle-1-bg

125

This test examines the 125 most important cancer genes.

results in 3 weeks
our-tests-circle-2-fallback
our-tests-circle-2-bg

20,766

This test comprehensively looks at 20,766 genes in the cancer cells.

results in 6 weeks
our-tests-circle-3-fallback
our-tests-circle-3-bg

64

This test evaluates a targeted panel of 64 well-characterizedcancer genes.

results in 2-3 weeks
MSI status reported for all clinical assays in
tissue and plasma.

How it Works

how-it-works-graphic-f1-s1 how-it-works-graphic-f1-s2

Who is eligible

Any patient with a cancer diagnosis that has been confirmed with a biopsy.
how-it-works-graphic-f2-s1 how-it-works-graphic-f2-s2

What we need

CancerSELECT™: Saliva & Tumor Samples 125 cancer gene panelCancerCOMPLETE®: Saliva & Tumor Samples 20,766 gene panelPlasmaSELECT™: Blood & Plasma Sample 64 gene panel

Follow Our 5-step process

  • Step one: dna extraction
    DNA is extracted, purified, and quantified using PGDx proprietary methods. Next generation sequencing libraries are then constructed.
  • Step two: generate sequence data
    Next generation sequencing will be performed to achieve high-coverage of the target regions included in the PlasmaSELECT™, CancerCOMPLETE® or CancerSELECT™ test.
  • Step three: analyze data

    CancerSELECT™: After the raw data is converted to DNA sequences, the tumor and normal data are compared, which allows for the detection of tumor-specific alterations, as well as quality control metrics across the targeted region.

    PlasmaSELECT™ 64: Tumor-specific mutations, copy number changes, and rearrangements are identified and annotated using proprietary PGDx algorithms.
  • Step four: identify mutations

    The tumor-specific mutations are identified, including sequence alterations, small insertions and deletions, copy number alterations and rearrangements.

    Tumor-specific mutations, copy number changes, and rearrangements are identified and annotated using proprietary PGDx algorithms.
  • Step five: final report

    Making sense of your cancer genome:

    All documented mutations will then be linked to clinical and biological information which may indicate how a particular tumor may respond to therapy, permit enrollment into an ongoing clinical trial, and provide other clinical and biologic aspects important in your tumor. Optional clinical trial enrollment support is available through our partner, Cure Forward. Read about how today's most cutting edge cancer treatements can be found in clinical trials with help from Cure Forward.
ViewProduct Information

Your Report

fbox-report

REPORT INCLUDES:

A list of possible treatment options specific for the genetic alterations found in your tumor.

These treatment options may include: • Clinical trials enrolling patients with your genetic alteration and tumor type • Therapies that are approved in your cancer type • Therapies that are approved in other cancer types

example report

your-report-report
your-report-z1
Point mutations
your-report-z2
Genetic alterations with established clinical significance
your-report-z3
Copy number or structural alterations
Download PlasmaSELECTexample report Download cancerSELECT™EXAMPLE REPORT
fbox-report

FINANCIAL ASSISTANCE

The PASS (PGDx Access Support Services) financial assistance program offers discounts to patients in compliance with US Department of Health and Human Services guidelines.

Eligibility is based on family size and income level.
Tiered discounts are available up to 100%.

To check your eligibility, submit an application form.

QUESTIONS?

Call us at 888-571-2163
or see below.

Contact Us

fbox-envelope

We love questions & comments

FAQ




CancerCOMPLETECancerSELECTPlasmaSELECTOther